<DOC>
	<DOC>NCT01525238</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)</brief_summary>
	<brief_title>PK Study of Dapagliflozin in Pediatric Subjects With T2DM</brief_title>
	<detailed_description>Primary purpose: The primary purpose is to assess the pharmacokinetics of a single dose of Dapagliflozin in the range of 2.5 to 10 mg in pediatric subjects aged 10 to 17 years with T2DM</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Clinical diagnosis of T2DM Male and female subjects ages 1017 Glycosylated Hemoglobin A1c (HbA1c) &gt;6 to &lt;10% Fasting plasma glucose (FPG) &gt;240 mg/dL at screening Abnormal renal function Active liver disease and/or significant abnormal liver function</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>